Navigation Links
PRA Early Phase Experts to Speak at Bioanalysis Conference
Date:11/15/2011

RALEIGH, N.C., Nov. 15, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that two of our Early Development Services (EDS) experts will present at the European Bioanalysis Forum Open Symposium being held in Barcelona, Spain 16-18 November 2011. PRA will also host an exhibit at booth #C3.

On 16 November at 14:45PM CET, Dr. Nico van de Merbel, Scientific Director at PRA's EDS Bioanalytical Laboratory in The Netherlands, will deliver a presentation titled, "Update on Harmonization of Bioanalytical Stability Determination, as part of the Global Bioanalysis Consortium (GBC) Initiative." Dr. van de Merbel's speech will outline his project team's recommendations for new bioanalytical harmonization guidelines.  

On the same day at 17:00PM CET, Dr. Barry W.A. van der Strate, a Senior Project Manager at PRA's EDS Bioanalytical Laboratory in The Netherlands, will present his paper, "Flow Cytometry for Determination of Efficacy in Phase I." Dr. van der Strate will review specific case studies to demonstrate how researchers can use flow cytometry during assay development to investigate compound efficacy for both in vitro and ex vivo trials.

At PRA's exhibit, representatives from our EDS, Business Development and Operations groups will be available to discuss how PRA can support drug development programs.

Dr. van de Merbel, who joined PRA in 1995, is an expert in quantitative bioanalytical chemistry. As PRA's scientific director of small molecule bioanalysis, he is responsible for the development and validation of novel methodologies that support pharmacokinetic and pharmacodynamic analysis in all phases of drug development. In addition, he serves as professor of Industrial Bioanalysis at the University of Groningen.

Dr. van der Strate received a Ph.D. in medical biology from the University of Groningen. He joined PRA in 2008 after completing post-doctorates in pulmonary emphysema and CD34+ cell therapy in neovascularization. As a senior project manager at PRA, Dr. van der Strate specializes in method development and validation of immunochemical assays.

PRA's EDS group conducts Phase I-IIa studies for pharmaceutical and biotechnology clients through our clinics in Europe and the U.S. with bioanalytical laboratories in close proximity to each, facilitating analysis of time-critical patient samples.  Additionally, we operate our Unit on Demand model in Central and Eastern Europe for early phase patient studies.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk
2. Cerebral Stethoscope Offers New Tool for Early Detection of Aneurysms
3. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
4. New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
5. Fighting Breast Cancer Early, One Cell At A Time
6. Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success
7. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
8. DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
9. President Obama Presents Early Career Award to Dr. Sumita Pennathur
10. Cancer Patients Can Benefit From Early Detection Of Heart Damage Using Echocardiography
11. Phreesias Digital Depression Screening Improves Early Detection and Drives Better Healthcare Outcomes in Medical Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):